nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—migraine—Prednisone—prostate cancer	0.289	1	CpDpCtD
Metoclopramide—CYP17A1—prostate cancer	0.262	1	CbGaD
Metoclopramide—CYP17A1—Abiraterone—prostate cancer	0.207	0.843	CbGbCtD
Metoclopramide—CYP2D6—Bicalutamide—prostate cancer	0.0194	0.079	CbGbCtD
Metoclopramide—CYP2D6—Abiraterone—prostate cancer	0.0161	0.0655	CbGbCtD
Metoclopramide—CYP2D6—Doxorubicin—prostate cancer	0.00298	0.0121	CbGbCtD
Metoclopramide—Sunitinib—IRAK4—prostate cancer	0.000497	0.145	CrCbGaD
Metoclopramide—Sunitinib—MAP3K7—prostate cancer	0.000377	0.11	CrCbGaD
Metoclopramide—Sunitinib—MAP2K1—prostate cancer	0.00032	0.0931	CrCbGaD
Metoclopramide—Sunitinib—CHEK2—prostate cancer	0.000256	0.0745	CrCbGaD
Metoclopramide—Sunitinib—JAK2—prostate cancer	0.000243	0.0706	CrCbGaD
Metoclopramide—Sunitinib—FGFR2—prostate cancer	0.000239	0.0694	CrCbGaD
Metoclopramide—Procainamide—DNMT1—prostate cancer	0.000223	0.0648	CrCbGaD
Metoclopramide—Sunitinib—PDGFRB—prostate cancer	0.000189	0.0549	CrCbGaD
Metoclopramide—Procainamide—SLC22A3—prostate cancer	0.000146	0.0424	CrCbGaD
Metoclopramide—Cisapride—CYP3A5—prostate cancer	0.000145	0.0422	CrCbGaD
Metoclopramide—Sunitinib—KDR—prostate cancer	0.000143	0.0416	CrCbGaD
Metoclopramide—Cisapride—CYP2A6—prostate cancer	0.000141	0.0409	CrCbGaD
Metoclopramide—Procainamide—ACHE—prostate cancer	0.000132	0.0383	CrCbGaD
Metoclopramide—Procainamide—SLC22A1—prostate cancer	0.000105	0.0304	CrCbGaD
Metoclopramide—Cisapride—CYP2C19—prostate cancer	9.89e-05	0.0287	CrCbGaD
Metoclopramide—Sunitinib—CYP3A5—prostate cancer	8.64e-05	0.0251	CrCbGaD
Metoclopramide—Feeling abnormal—Goserelin—prostate cancer	7.72e-05	0.000756	CcSEcCtD
Metoclopramide—Neutropenia—Capecitabine—prostate cancer	7.62e-05	0.000746	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—prostate cancer	7.61e-05	0.000745	CcSEcCtD
Metoclopramide—Leukopenia—Mitoxantrone—prostate cancer	7.59e-05	0.000743	CcSEcCtD
Metoclopramide—Dizziness—Ethinyl Estradiol—prostate cancer	7.53e-05	0.000737	CcSEcCtD
Metoclopramide—Flushing—Etoposide—prostate cancer	7.52e-05	0.000736	CcSEcCtD
Metoclopramide—Confusional state—Estradiol—prostate cancer	7.49e-05	0.000733	CcSEcCtD
Metoclopramide—Urticaria—Goserelin—prostate cancer	7.45e-05	0.000729	CcSEcCtD
Metoclopramide—Oedema—Estradiol—prostate cancer	7.43e-05	0.000727	CcSEcCtD
Metoclopramide—Body temperature increased—Goserelin—prostate cancer	7.41e-05	0.000725	CcSEcCtD
Metoclopramide—Urticaria—Conjugated Estrogens—prostate cancer	7.37e-05	0.000722	CcSEcCtD
Metoclopramide—Convulsion—Mitoxantrone—prostate cancer	7.35e-05	0.000719	CcSEcCtD
Metoclopramide—Body temperature increased—Conjugated Estrogens—prostate cancer	7.34e-05	0.000718	CcSEcCtD
Metoclopramide—Hypertension—Mitoxantrone—prostate cancer	7.32e-05	0.000717	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—prostate cancer	7.31e-05	0.000716	CcSEcCtD
Metoclopramide—Tachycardia—Estradiol—prostate cancer	7.25e-05	0.00071	CcSEcCtD
Metoclopramide—Depression—Capecitabine—prostate cancer	7.24e-05	0.000709	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—prostate cancer	7.24e-05	0.000709	CcSEcCtD
Metoclopramide—Anxiety—Mitoxantrone—prostate cancer	7.2e-05	0.000704	CcSEcCtD
Metoclopramide—Rash—Ethinyl Estradiol—prostate cancer	7.18e-05	0.000703	CcSEcCtD
Metoclopramide—Dermatitis—Ethinyl Estradiol—prostate cancer	7.17e-05	0.000702	CcSEcCtD
Metoclopramide—Headache—Ethinyl Estradiol—prostate cancer	7.13e-05	0.000698	CcSEcCtD
Metoclopramide—Jaundice—Capecitabine—prostate cancer	7.08e-05	0.000693	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—prostate cancer	7e-05	0.000685	CcSEcCtD
Metoclopramide—Confusional state—Mitoxantrone—prostate cancer	6.98e-05	0.000683	CcSEcCtD
Metoclopramide—Oedema—Mitoxantrone—prostate cancer	6.92e-05	0.000678	CcSEcCtD
Metoclopramide—Hypersensitivity—Goserelin—prostate cancer	6.9e-05	0.000676	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—prostate cancer	6.9e-05	0.000675	CcSEcCtD
Metoclopramide—Hypersensitivity—Conjugated Estrogens—prostate cancer	6.84e-05	0.000669	CcSEcCtD
Metoclopramide—Neutropenia—Prednisone—prostate cancer	6.79e-05	0.000664	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—prostate cancer	6.78e-05	0.000664	CcSEcCtD
Metoclopramide—Agranulocytosis—Capecitabine—prostate cancer	6.78e-05	0.000664	CcSEcCtD
Metoclopramide—Nausea—Ethinyl Estradiol—prostate cancer	6.76e-05	0.000662	CcSEcCtD
Metoclopramide—Tachycardia—Mitoxantrone—prostate cancer	6.76e-05	0.000661	CcSEcCtD
Metoclopramide—Asthenia—Goserelin—prostate cancer	6.72e-05	0.000658	CcSEcCtD
Metoclopramide—Insomnia—Estradiol—prostate cancer	6.72e-05	0.000658	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—prostate cancer	6.7e-05	0.000656	CcSEcCtD
Metoclopramide—Erectile dysfunction—Prednisone—prostate cancer	6.68e-05	0.000654	CcSEcCtD
Metoclopramide—Asthenia—Conjugated Estrogens—prostate cancer	6.66e-05	0.000652	CcSEcCtD
Metoclopramide—Bradycardia—Capecitabine—prostate cancer	6.64e-05	0.00065	CcSEcCtD
Metoclopramide—Dyspnoea—Estradiol—prostate cancer	6.62e-05	0.000648	CcSEcCtD
Metoclopramide—Somnolence—Estradiol—prostate cancer	6.6e-05	0.000646	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—prostate cancer	6.49e-05	0.000635	CcSEcCtD
Metoclopramide—Hypotension—Mitoxantrone—prostate cancer	6.47e-05	0.000633	CcSEcCtD
Metoclopramide—Depression—Prednisone—prostate cancer	6.45e-05	0.000632	CcSEcCtD
Metoclopramide—Diarrhoea—Goserelin—prostate cancer	6.41e-05	0.000628	CcSEcCtD
Metoclopramide—Fatigue—Estradiol—prostate cancer	6.41e-05	0.000627	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—prostate cancer	6.38e-05	0.000625	CcSEcCtD
Metoclopramide—Diarrhoea—Conjugated Estrogens—prostate cancer	6.35e-05	0.000622	CcSEcCtD
Metoclopramide—Leukopenia—Etoposide—prostate cancer	6.32e-05	0.000618	CcSEcCtD
Metoclopramide—Cisapride—CYP3A4—prostate cancer	6.29e-05	0.0183	CrCbGaD
Metoclopramide—Visual impairment—Capecitabine—prostate cancer	6.28e-05	0.000615	CcSEcCtD
Metoclopramide—Flushing—Docetaxel—prostate cancer	6.25e-05	0.000612	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—prostate cancer	6.24e-05	0.000611	CcSEcCtD
Metoclopramide—Dizziness—Goserelin—prostate cancer	6.2e-05	0.000607	CcSEcCtD
Metoclopramide—Dyspnoea—Mitoxantrone—prostate cancer	6.17e-05	0.000604	CcSEcCtD
Metoclopramide—Somnolence—Mitoxantrone—prostate cancer	6.15e-05	0.000602	CcSEcCtD
Metoclopramide—Dizziness—Conjugated Estrogens—prostate cancer	6.14e-05	0.000601	CcSEcCtD
Metoclopramide—Feeling abnormal—Estradiol—prostate cancer	6.12e-05	0.000599	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—prostate cancer	6.11e-05	0.000598	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—prostate cancer	6.09e-05	0.000596	CcSEcCtD
Metoclopramide—Flushing—Capecitabine—prostate cancer	6.05e-05	0.000592	CcSEcCtD
Metoclopramide—Fatigue—Mitoxantrone—prostate cancer	5.97e-05	0.000584	CcSEcCtD
Metoclopramide—Bradycardia—Prednisone—prostate cancer	5.91e-05	0.000579	CcSEcCtD
Metoclopramide—Rash—Goserelin—prostate cancer	5.91e-05	0.000578	CcSEcCtD
Metoclopramide—Dermatitis—Goserelin—prostate cancer	5.9e-05	0.000578	CcSEcCtD
Metoclopramide—Urticaria—Estradiol—prostate cancer	5.9e-05	0.000578	CcSEcCtD
Metoclopramide—Body temperature increased—Estradiol—prostate cancer	5.87e-05	0.000575	CcSEcCtD
Metoclopramide—Headache—Goserelin—prostate cancer	5.87e-05	0.000575	CcSEcCtD
Metoclopramide—Rash—Conjugated Estrogens—prostate cancer	5.85e-05	0.000573	CcSEcCtD
Metoclopramide—Dermatitis—Conjugated Estrogens—prostate cancer	5.85e-05	0.000572	CcSEcCtD
Metoclopramide—Headache—Conjugated Estrogens—prostate cancer	5.82e-05	0.000569	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—prostate cancer	5.81e-05	0.000568	CcSEcCtD
Metoclopramide—Hallucination—Prednisone—prostate cancer	5.78e-05	0.000566	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—prostate cancer	5.78e-05	0.000566	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitoxantrone—prostate cancer	5.7e-05	0.000558	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—prostate cancer	5.68e-05	0.000556	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—prostate cancer	5.64e-05	0.000552	CcSEcCtD
Metoclopramide—Tachycardia—Etoposide—prostate cancer	5.62e-05	0.00055	CcSEcCtD
Metoclopramide—Nausea—Goserelin—prostate cancer	5.57e-05	0.000545	CcSEcCtD
Metoclopramide—Nausea—Conjugated Estrogens—prostate cancer	5.51e-05	0.00054	CcSEcCtD
Metoclopramide—Urticaria—Mitoxantrone—prostate cancer	5.5e-05	0.000538	CcSEcCtD
Metoclopramide—Hypersensitivity—Estradiol—prostate cancer	5.47e-05	0.000536	CcSEcCtD
Metoclopramide—Body temperature increased—Mitoxantrone—prostate cancer	5.47e-05	0.000536	CcSEcCtD
Metoclopramide—Muscle spasms—Capecitabine—prostate cancer	5.46e-05	0.000534	CcSEcCtD
Metoclopramide—Flushing—Prednisone—prostate cancer	5.39e-05	0.000528	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—prostate cancer	5.38e-05	0.000527	CcSEcCtD
Metoclopramide—Asthenia—Estradiol—prostate cancer	5.33e-05	0.000522	CcSEcCtD
Metoclopramide—Tremor—Capecitabine—prostate cancer	5.32e-05	0.000521	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—prostate cancer	5.31e-05	0.00052	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—prostate cancer	5.25e-05	0.000514	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—prostate cancer	5.25e-05	0.000514	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—prostate cancer	5.24e-05	0.000513	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—prostate cancer	5.18e-05	0.000507	CcSEcCtD
Metoclopramide—Dyspnoea—Etoposide—prostate cancer	5.13e-05	0.000502	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—prostate cancer	5.12e-05	0.000501	CcSEcCtD
Metoclopramide—Hypersensitivity—Mitoxantrone—prostate cancer	5.1e-05	0.000499	CcSEcCtD
Metoclopramide—Diarrhoea—Estradiol—prostate cancer	5.08e-05	0.000498	CcSEcCtD
Metoclopramide—Leukopenia—Capecitabine—prostate cancer	5.08e-05	0.000497	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—prostate cancer	5.08e-05	0.000497	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—prostate cancer	5.06e-05	0.000496	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—prostate cancer	5.06e-05	0.000495	CcSEcCtD
Metoclopramide—Palpitations—Capecitabine—prostate cancer	5.02e-05	0.000491	CcSEcCtD
Metoclopramide—Asthenia—Mitoxantrone—prostate cancer	4.97e-05	0.000486	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—prostate cancer	4.96e-05	0.000486	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—prostate cancer	4.93e-05	0.000483	CcSEcCtD
Metoclopramide—Dizziness—Estradiol—prostate cancer	4.91e-05	0.000481	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—prostate cancer	4.91e-05	0.000481	CcSEcCtD
Metoclopramide—Hypertension—Capecitabine—prostate cancer	4.9e-05	0.00048	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—prostate cancer	4.85e-05	0.000475	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—prostate cancer	4.83e-05	0.000472	CcSEcCtD
Metoclopramide—Anxiety—Capecitabine—prostate cancer	4.82e-05	0.000471	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—prostate cancer	4.79e-05	0.000468	CcSEcCtD
Metoclopramide—Feeling abnormal—Etoposide—prostate cancer	4.75e-05	0.000464	CcSEcCtD
Metoclopramide—Diarrhoea—Mitoxantrone—prostate cancer	4.74e-05	0.000464	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—prostate cancer	4.72e-05	0.000462	CcSEcCtD
Metoclopramide—Rash—Estradiol—prostate cancer	4.68e-05	0.000459	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—prostate cancer	4.68e-05	0.000458	CcSEcCtD
Metoclopramide—Dermatitis—Estradiol—prostate cancer	4.68e-05	0.000458	CcSEcCtD
Metoclopramide—Confusional state—Capecitabine—prostate cancer	4.67e-05	0.000457	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—prostate cancer	4.67e-05	0.000457	CcSEcCtD
Metoclopramide—Headache—Estradiol—prostate cancer	4.65e-05	0.000456	CcSEcCtD
Metoclopramide—Agitation—Prednisone—prostate cancer	4.65e-05	0.000455	CcSEcCtD
Metoclopramide—Oedema—Capecitabine—prostate cancer	4.63e-05	0.000454	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—prostate cancer	4.63e-05	0.000453	CcSEcCtD
Metoclopramide—Angioedema—Prednisone—prostate cancer	4.62e-05	0.000452	CcSEcCtD
Metoclopramide—Urticaria—Etoposide—prostate cancer	4.57e-05	0.000448	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—prostate cancer	4.56e-05	0.000447	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—prostate cancer	4.55e-05	0.000446	CcSEcCtD
Metoclopramide—Tachycardia—Capecitabine—prostate cancer	4.52e-05	0.000443	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—prostate cancer	4.47e-05	0.000438	CcSEcCtD
Metoclopramide—Nausea—Estradiol—prostate cancer	4.41e-05	0.000432	CcSEcCtD
Metoclopramide—Convulsion—Prednisone—prostate cancer	4.38e-05	0.000429	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—prostate cancer	4.38e-05	0.000429	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—prostate cancer	4.37e-05	0.000428	CcSEcCtD
Metoclopramide—Hypertension—Prednisone—prostate cancer	4.37e-05	0.000427	CcSEcCtD
Metoclopramide—Rash—Mitoxantrone—prostate cancer	4.36e-05	0.000427	CcSEcCtD
Metoclopramide—Dermatitis—Mitoxantrone—prostate cancer	4.36e-05	0.000427	CcSEcCtD
Metoclopramide—Headache—Mitoxantrone—prostate cancer	4.34e-05	0.000424	CcSEcCtD
Metoclopramide—Hypotension—Capecitabine—prostate cancer	4.33e-05	0.000424	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—prostate cancer	4.33e-05	0.000424	CcSEcCtD
Metoclopramide—Anxiety—Prednisone—prostate cancer	4.29e-05	0.00042	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—prostate cancer	4.28e-05	0.000419	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—prostate cancer	4.27e-05	0.000418	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—prostate cancer	4.25e-05	0.000416	CcSEcCtD
Metoclopramide—Hypersensitivity—Etoposide—prostate cancer	4.24e-05	0.000415	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—prostate cancer	4.22e-05	0.000413	CcSEcCtD
Metoclopramide—Insomnia—Capecitabine—prostate cancer	4.19e-05	0.00041	CcSEcCtD
Metoclopramide—Asthenia—Etoposide—prostate cancer	4.13e-05	0.000404	CcSEcCtD
Metoclopramide—Dyspnoea—Capecitabine—prostate cancer	4.13e-05	0.000404	CcSEcCtD
Metoclopramide—Oedema—Prednisone—prostate cancer	4.13e-05	0.000404	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—prostate cancer	4.13e-05	0.000404	CcSEcCtD
Metoclopramide—Nausea—Mitoxantrone—prostate cancer	4.11e-05	0.000402	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—prostate cancer	4.05e-05	0.000397	CcSEcCtD
Metoclopramide—Tachycardia—Prednisone—prostate cancer	4.03e-05	0.000394	CcSEcCtD
Metoclopramide—Fatigue—Capecitabine—prostate cancer	3.99e-05	0.000391	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—prostate cancer	3.94e-05	0.000386	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—prostate cancer	3.94e-05	0.000386	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—prostate cancer	3.9e-05	0.000382	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—prostate cancer	3.84e-05	0.000376	CcSEcCtD
Metoclopramide—Feeling abnormal—Capecitabine—prostate cancer	3.82e-05	0.000374	CcSEcCtD
Metoclopramide—Dizziness—Etoposide—prostate cancer	3.81e-05	0.000373	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—prostate cancer	3.8e-05	0.000372	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—prostate cancer	3.78e-05	0.00037	CcSEcCtD
Metoclopramide—Sunitinib—CYP3A4—prostate cancer	3.74e-05	0.0109	CrCbGaD
Metoclopramide—Insomnia—Prednisone—prostate cancer	3.73e-05	0.000365	CcSEcCtD
Metoclopramide—Urticaria—Capecitabine—prostate cancer	3.68e-05	0.00036	CcSEcCtD
Metoclopramide—Body temperature increased—Capecitabine—prostate cancer	3.66e-05	0.000358	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—prostate cancer	3.63e-05	0.000356	CcSEcCtD
Metoclopramide—Rash—Etoposide—prostate cancer	3.63e-05	0.000355	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—prostate cancer	3.63e-05	0.000355	CcSEcCtD
Metoclopramide—Headache—Etoposide—prostate cancer	3.61e-05	0.000353	CcSEcCtD
Metoclopramide—Fatigue—Prednisone—prostate cancer	3.56e-05	0.000348	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—prostate cancer	3.55e-05	0.000348	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—prostate cancer	3.54e-05	0.000347	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—prostate cancer	3.53e-05	0.000345	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—prostate cancer	3.52e-05	0.000344	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—prostate cancer	3.5e-05	0.000342	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—prostate cancer	3.43e-05	0.000336	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—prostate cancer	3.43e-05	0.000335	CcSEcCtD
Metoclopramide—Nausea—Etoposide—prostate cancer	3.42e-05	0.000335	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—prostate cancer	3.41e-05	0.000334	CcSEcCtD
Metoclopramide—Hypersensitivity—Capecitabine—prostate cancer	3.41e-05	0.000334	CcSEcCtD
Metoclopramide—Feeling abnormal—Prednisone—prostate cancer	3.4e-05	0.000333	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—prostate cancer	3.36e-05	0.000329	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—prostate cancer	3.36e-05	0.000328	CcSEcCtD
Metoclopramide—Asthenia—Capecitabine—prostate cancer	3.32e-05	0.000325	CcSEcCtD
Metoclopramide—Urticaria—Prednisone—prostate cancer	3.28e-05	0.000321	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—prostate cancer	3.28e-05	0.000321	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—prostate cancer	3.27e-05	0.00032	CcSEcCtD
Metoclopramide—Body temperature increased—Prednisone—prostate cancer	3.26e-05	0.000319	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—prostate cancer	3.25e-05	0.000319	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—prostate cancer	3.23e-05	0.000317	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—prostate cancer	3.23e-05	0.000316	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—prostate cancer	3.17e-05	0.00031	CcSEcCtD
Metoclopramide—Diarrhoea—Capecitabine—prostate cancer	3.17e-05	0.00031	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—prostate cancer	3.16e-05	0.00031	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—prostate cancer	3.16e-05	0.000309	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—prostate cancer	3.15e-05	0.000308	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—prostate cancer	3.1e-05	0.000304	CcSEcCtD
Metoclopramide—Dizziness—Capecitabine—prostate cancer	3.06e-05	0.0003	CcSEcCtD
Metoclopramide—Hypersensitivity—Prednisone—prostate cancer	3.04e-05	0.000298	CcSEcCtD
Metoclopramide—Rash—Docetaxel—prostate cancer	3.02e-05	0.000295	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—prostate cancer	3.02e-05	0.000295	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—prostate cancer	3.01e-05	0.000295	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—prostate cancer	3.01e-05	0.000295	CcSEcCtD
Metoclopramide—Headache—Docetaxel—prostate cancer	3e-05	0.000293	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—prostate cancer	2.99e-05	0.000292	CcSEcCtD
Metoclopramide—Asthenia—Prednisone—prostate cancer	2.96e-05	0.00029	CcSEcCtD
Metoclopramide—Rash—Capecitabine—prostate cancer	2.92e-05	0.000286	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—prostate cancer	2.92e-05	0.000286	CcSEcCtD
Metoclopramide—Dermatitis—Capecitabine—prostate cancer	2.92e-05	0.000286	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—prostate cancer	2.91e-05	0.000285	CcSEcCtD
Metoclopramide—Headache—Capecitabine—prostate cancer	2.9e-05	0.000284	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—prostate cancer	2.88e-05	0.000282	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—prostate cancer	2.87e-05	0.000281	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—prostate cancer	2.84e-05	0.000278	CcSEcCtD
Metoclopramide—Diarrhoea—Prednisone—prostate cancer	2.82e-05	0.000276	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—prostate cancer	2.79e-05	0.000273	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—prostate cancer	2.78e-05	0.000272	CcSEcCtD
Metoclopramide—Nausea—Capecitabine—prostate cancer	2.75e-05	0.000269	CcSEcCtD
Metoclopramide—Dizziness—Prednisone—prostate cancer	2.73e-05	0.000267	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—prostate cancer	2.7e-05	0.000264	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—prostate cancer	2.66e-05	0.000261	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—prostate cancer	2.66e-05	0.00026	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—prostate cancer	2.66e-05	0.00026	CcSEcCtD
Metoclopramide—Rash—Prednisone—prostate cancer	2.6e-05	0.000255	CcSEcCtD
Metoclopramide—Dermatitis—Prednisone—prostate cancer	2.6e-05	0.000254	CcSEcCtD
Metoclopramide—Headache—Prednisone—prostate cancer	2.59e-05	0.000253	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—prostate cancer	2.57e-05	0.000252	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—prostate cancer	2.56e-05	0.000251	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—prostate cancer	2.55e-05	0.00025	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—prostate cancer	2.46e-05	0.000241	CcSEcCtD
Metoclopramide—Nausea—Prednisone—prostate cancer	2.45e-05	0.00024	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—prostate cancer	2.38e-05	0.000233	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—prostate cancer	2.37e-05	0.000232	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—prostate cancer	2.36e-05	0.000231	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—prostate cancer	2.32e-05	0.000227	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—prostate cancer	2.21e-05	0.000216	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—prostate cancer	2.2e-05	0.000215	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—prostate cancer	2.14e-05	0.00021	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—prostate cancer	2.13e-05	0.000209	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—prostate cancer	2.04e-05	0.0002	CcSEcCtD
Metoclopramide—Rash—Epirubicin—prostate cancer	2.04e-05	0.000199	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—prostate cancer	2.03e-05	0.000199	CcSEcCtD
Metoclopramide—Headache—Epirubicin—prostate cancer	2.02e-05	0.000198	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—prostate cancer	1.97e-05	0.000193	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—prostate cancer	1.92e-05	0.000188	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—prostate cancer	1.88e-05	0.000184	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—prostate cancer	1.88e-05	0.000184	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—prostate cancer	1.87e-05	0.000183	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—prostate cancer	1.77e-05	0.000174	CcSEcCtD
Metoclopramide—CHRM1—Signaling Pathways—NGFR—prostate cancer	2.48e-06	2.54e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAP3K7—prostate cancer	2.45e-06	2.51e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—prostate cancer	2.44e-06	2.49e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—prostate cancer	2.43e-06	2.48e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGF10—prostate cancer	2.41e-06	2.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRB2—prostate cancer	2.39e-06	2.44e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HPGDS—prostate cancer	2.38e-06	2.43e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2C19—prostate cancer	2.37e-06	2.42e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGF10—prostate cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—JAK2—prostate cancer	2.35e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAP2K1—prostate cancer	2.34e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—prostate cancer	2.34e-06	2.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRB2—prostate cancer	2.34e-06	2.39e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CD—prostate cancer	2.33e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VAV3—prostate cancer	2.33e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—prostate cancer	2.32e-06	2.37e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—prostate cancer	2.32e-06	2.37e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTT1—prostate cancer	2.31e-06	2.36e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ACHE—prostate cancer	2.31e-06	2.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—JAK2—prostate cancer	2.3e-06	2.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAP2K1—prostate cancer	2.29e-06	2.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFBR2—prostate cancer	2.29e-06	2.34e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2A6—prostate cancer	2.28e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CD—prostate cancer	2.28e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VAV3—prostate cancer	2.28e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—prostate cancer	2.27e-06	2.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ITPR1—prostate cancer	2.26e-06	2.31e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CAV1—prostate cancer	2.25e-06	2.29e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFBR2—prostate cancer	2.25e-06	2.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CB—prostate cancer	2.24e-06	2.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KDR—prostate cancer	2.22e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C3—prostate cancer	2.22e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ITPR1—prostate cancer	2.21e-06	2.26e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PRKACB—prostate cancer	2.21e-06	2.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CB—prostate cancer	2.19e-06	2.24e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP17A1—prostate cancer	2.19e-06	2.23e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—prostate cancer	2.16e-06	2.21e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—prostate cancer	2.16e-06	2.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—prostate cancer	2.15e-06	2.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—JAK2—prostate cancer	2.14e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—prostate cancer	2.14e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—prostate cancer	2.11e-06	2.16e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BAD—prostate cancer	2.11e-06	2.16e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—prostate cancer	2.1e-06	2.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—JAK2—prostate cancer	2.09e-06	2.14e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOA2—prostate cancer	2.08e-06	2.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LPL—prostate cancer	2.07e-06	2.11e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—prostate cancer	2.05e-06	2.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PDGFRB—prostate cancer	2.05e-06	2.09e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—prostate cancer	2.05e-06	2.09e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—prostate cancer	2.05e-06	2.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CB—prostate cancer	2.03e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LPL—prostate cancer	2.03e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGF—prostate cancer	2.02e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS1—prostate cancer	2.02e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—prostate cancer	2.02e-06	2.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—prostate cancer	2.01e-06	2.05e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PDGFRB—prostate cancer	2.01e-06	2.05e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ITGB3—prostate cancer	2e-06	2.04e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CB—prostate cancer	1.99e-06	2.03e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.99e-06	2.03e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GSK3B—prostate cancer	1.96e-06	2.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ITGB3—prostate cancer	1.96e-06	2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—prostate cancer	1.95e-06	1.99e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB3—prostate cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INS—prostate cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR2—prostate cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NQO1—prostate cancer	1.92e-06	1.96e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—prostate cancer	1.91e-06	1.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	1.91e-06	1.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB3—prostate cancer	1.9e-06	1.94e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CREBBP—prostate cancer	1.9e-06	1.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR2—prostate cancer	1.89e-06	1.93e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TH—prostate cancer	1.89e-06	1.93e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—prostate cancer	1.89e-06	1.93e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—prostate cancer	1.87e-06	1.91e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.87e-06	1.91e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—prostate cancer	1.86e-06	1.9e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—prostate cancer	1.86e-06	1.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—prostate cancer	1.86e-06	1.9e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.84e-06	1.88e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—prostate cancer	1.82e-06	1.86e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—prostate cancer	1.82e-06	1.86e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAP2K1—prostate cancer	1.81e-06	1.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CD—prostate cancer	1.8e-06	1.84e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GGT1—prostate cancer	1.78e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—prostate cancer	1.78e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—prostate cancer	1.78e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—prostate cancer	1.78e-06	1.81e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—prostate cancer	1.76e-06	1.8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOA1—prostate cancer	1.75e-06	1.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—prostate cancer	1.74e-06	1.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—prostate cancer	1.73e-06	1.77e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.73e-06	1.77e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGF2—prostate cancer	1.72e-06	1.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CAV1—prostate cancer	1.72e-06	1.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KDR—prostate cancer	1.7e-06	1.74e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOS3—prostate cancer	1.7e-06	1.73e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—prostate cancer	1.7e-06	1.73e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CAV1—prostate cancer	1.68e-06	1.72e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RXRA—prostate cancer	1.67e-06	1.7e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KDR—prostate cancer	1.66e-06	1.7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—prostate cancer	1.66e-06	1.69e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JAK2—prostate cancer	1.65e-06	1.69e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—prostate cancer	1.65e-06	1.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—prostate cancer	1.62e-06	1.66e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—prostate cancer	1.62e-06	1.65e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BAD—prostate cancer	1.62e-06	1.65e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MDM2—prostate cancer	1.61e-06	1.65e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—COMT—prostate cancer	1.61e-06	1.64e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—prostate cancer	1.6e-06	1.63e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—prostate cancer	1.59e-06	1.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BAD—prostate cancer	1.58e-06	1.62e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ITPR1—prostate cancer	1.57e-06	1.61e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CB—prostate cancer	1.57e-06	1.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—prostate cancer	1.57e-06	1.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—prostate cancer	1.57e-06	1.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS1—prostate cancer	1.55e-06	1.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGF—prostate cancer	1.55e-06	1.58e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—prostate cancer	1.54e-06	1.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—prostate cancer	1.53e-06	1.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	1.53e-06	1.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGF—prostate cancer	1.51e-06	1.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS1—prostate cancer	1.51e-06	1.55e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—prostate cancer	1.51e-06	1.54e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GSK3B—prostate cancer	1.5e-06	1.53e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—prostate cancer	1.49e-06	1.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INS—prostate cancer	1.48e-06	1.51e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—prostate cancer	1.47e-06	1.5e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—prostate cancer	1.47e-06	1.5e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GSK3B—prostate cancer	1.47e-06	1.5e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—prostate cancer	1.46e-06	1.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CREBBP—prostate cancer	1.45e-06	1.48e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INS—prostate cancer	1.45e-06	1.48e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPL—prostate cancer	1.44e-06	1.47e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—prostate cancer	1.44e-06	1.47e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—prostate cancer	1.44e-06	1.47e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—prostate cancer	1.43e-06	1.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—prostate cancer	1.43e-06	1.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—prostate cancer	1.43e-06	1.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CREBBP—prostate cancer	1.42e-06	1.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—prostate cancer	1.4e-06	1.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—prostate cancer	1.4e-06	1.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—prostate cancer	1.4e-06	1.43e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.39e-06	1.42e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—prostate cancer	1.39e-06	1.42e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAP2K1—prostate cancer	1.39e-06	1.41e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ERCC2—prostate cancer	1.38e-06	1.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CD—prostate cancer	1.38e-06	1.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	1.36e-06	1.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—prostate cancer	1.36e-06	1.39e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—prostate cancer	1.36e-06	1.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1A—prostate cancer	1.36e-06	1.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.36e-06	1.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—prostate cancer	1.35e-06	1.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—prostate cancer	1.35e-06	1.38e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.35e-06	1.38e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.33e-06	1.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.33e-06	1.36e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—prostate cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGF2—prostate cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—prostate cancer	1.3e-06	1.33e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOS3—prostate cancer	1.3e-06	1.33e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EP300—prostate cancer	1.29e-06	1.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.29e-06	1.32e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARA—prostate cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.27e-06	1.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JAK2—prostate cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—prostate cancer	1.26e-06	1.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	1.24e-06	1.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.24e-06	1.26e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MDM2—prostate cancer	1.23e-06	1.26e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—prostate cancer	1.22e-06	1.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—prostate cancer	1.22e-06	1.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—prostate cancer	1.21e-06	1.24e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.21e-06	1.24e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.21e-06	1.23e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CB—prostate cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAV1—prostate cancer	1.2e-06	1.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.17e-06	1.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—prostate cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—prostate cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—prostate cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—prostate cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—prostate cancer	1.11e-06	1.14e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—prostate cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—prostate cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—prostate cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—prostate cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.08e-06	1.1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—prostate cancer	1.08e-06	1.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—prostate cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—prostate cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.05e-06	1.07e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1A—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—INS—prostate cancer	1.03e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CREBBP—prostate cancer	1.01e-06	1.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.01e-06	1.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—prostate cancer	9.9e-07	1.01e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EP300—prostate cancer	9.88e-07	1.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EP300—prostate cancer	9.67e-07	9.88e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—prostate cancer	9.61e-07	9.82e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.6e-07	9.81e-06	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—prostate cancer	9.56e-07	9.76e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—prostate cancer	9.41e-07	9.61e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—prostate cancer	9.36e-07	9.56e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—prostate cancer	9.27e-07	9.47e-06	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—prostate cancer	9.24e-07	9.44e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—prostate cancer	9.16e-07	9.36e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—prostate cancer	9.07e-07	9.27e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NOS3—prostate cancer	9.06e-07	9.26e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—prostate cancer	8.61e-07	8.8e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—prostate cancer	8.59e-07	8.78e-06	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—prostate cancer	8.46e-07	8.64e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—prostate cancer	8.43e-07	8.61e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—prostate cancer	8.42e-07	8.61e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—prostate cancer	8.41e-07	8.59e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CB—prostate cancer	8.37e-07	8.55e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—prostate cancer	8.29e-07	8.47e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—prostate cancer	8.24e-07	8.42e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—prostate cancer	7.96e-07	8.13e-06	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—prostate cancer	7.81e-07	7.97e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—prostate cancer	7.79e-07	7.96e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—prostate cancer	7.31e-07	7.47e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—prostate cancer	7.23e-07	7.39e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	7.16e-07	7.31e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—prostate cancer	7.07e-07	7.23e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—prostate cancer	6.92e-07	7.07e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—EP300—prostate cancer	6.9e-07	7.04e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—prostate cancer	6.47e-07	6.61e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—prostate cancer	6.34e-07	6.47e-06	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—prostate cancer	5.97e-07	6.1e-06	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—prostate cancer	5.85e-07	5.97e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.1e-07	5.21e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—prostate cancer	4.17e-07	4.26e-06	CbGpPWpGaD
